RT Journal Article
T1 Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).
A1 Perez, Marco
A1 Peinado-Serrano, Javier
A1 Garcia-Heredia, Jose Manuel
A1 Felipe-Abrio, Irene
A1 Tous, Cristina
A1 Ferrer, Irene
A1 Martin-Broto, Javier
A1 Saez, Carmen
A1 Carnero, Amancio
K1 MAP17
K1 biomarker
K1 bortezomib
K1 sarcomas
K1 PDX
AB Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults. Surgery and radiation therapy are the accepted treatments for most sarcomas; however, patients with metastatic disease are treated with systemic chemotherapy. Many tumors display marginal levels of chemoresponsiveness, and new treatment approaches are needed. MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. The levels of MAP17 could be used as a prognostic marker to predict the response to bortezomib in hematological malignancies and in breast tumors. Therefore, we analyzed the expression of this oncogene in sarcomas and its relationship with clinico-pathological features, as well as tested whether it can be used as a new biomarker to predict the therapeutic response to bortezomib and new therapies for sarcomas. We found that the levels of MAP17 were related to clinical features and poor survival in a cohort of 69 patients with different sarcoma types, not being restricted to any special subtype of tumor. MAP17 expression is associated with poor overall survival (p
YR 2016
FD 2016
LK http://hdl.handle.net/10668/10392
UL http://hdl.handle.net/10668/10392
LA en
DS RISalud
RD Apr 7, 2025